Indirect measurement of Epstein-Barr virus neutralising antibodies by ELISA

Journal of Virological Methods

Volumn 73, Issue 1, 1998, Pages 11-19

  Wilson, A Douglas ^a   Morgan, Andrew J ^a  

^a UNIVERSITY OF BRISTOL   (United Kingdom)

Author keywords

ELISA; Epstein Barr virus; Neutralising antibody

Indexed keywords

NEUTRALIZING ANTIBODY;

ARTICLE; BIOASSAY; BLOOD ANALYSIS; ENZYME LINKED IMMUNOSORBENT ASSAY; EPSTEIN BARR VIRUS; HUMAN; HUMAN TISSUE; IMMUNOASSAY; INTERMETHOD COMPARISON; PRIORITY JOURNAL; TECHNIQUE; VIRUS CELL TRANSFORMATION;

ANTIBODIES, BLOCKING; ANTIBODIES, MONOCLONAL; ANTIBODIES, VIRAL; BINDING, COMPETITIVE; CELL TRANSFORMATION, VIRAL; ENZYME-LINKED IMMUNOSORBENT ASSAY; FETAL BLOOD; HERPESVIRUS 4, HUMAN; HUMANS; IMMUNE SERA; LYMPHOCYTES; NEUTRALIZATION TESTS; RECOMBINANT PROTEINS; REGRESSION ANALYSIS; VIRAL MATRIX PROTEINS;

EID: 0031718642     PISSN: 01660934     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0166-0934(98)00054-8     Document Type: Article

References (25)

1. Cleary M.L., Epstein M.A., Finerty S., Dorfman R.F., Bornkamm G.W., Kirkwood J.K., Morgan A.J., Sklar J. Individual tumors of multifocal EB virus-induced malignant lymphomas in tamarins arise from different B-cell clones. Science. 228:1985;722-724.
2. De Schryver A., Klein G., Hewetson J., Rocchi G., Henlé W., Henlé G., Moss D.J., Pope J.H. Comparison of EBV neutralization tests based on abortive infection or transformation of lymphoid cells and their relation to membrane reactive antibodies (anti MA). Int. J. Cancer. 13:1974;353-362.
3. Finerty S., Tarlton J., Mackett M., Conway M., Arrand J.R., Watkins P.E., Morgan A.J. Protective immunization against Epstein-Barr virus-induced disease in cottontop tamarins using the virus envelope glycoprotein gp340 produced from a bovine papillomavirus expression vector. J. Gen. Virol. 73:1992;449-453.
4. Hessing M., van Schijndel H.B., van Grunsven W.M., Wolf H., Middeldorp J. Purification and quantification of recombinant Epstein-Barr viral glycoproteins gp350/220 from Chinese hamster ovary cells. J. Chromatogr. 599:1992;267-272.
5. Hoffman G.J., Lazarowitz S.G., Hayward S.D. Monoclonal antibody against a 250000-dalton glycoprotein of Epstein-Barr virus identifies a membrane antigen and a neutralizing antigen. Proc. Natl. Acad. Sci. USA. 77:1980;2979-2983.
6. Lowe R.S., Keller P.M., Keech B.J., Davison A.J., Whang Y., Morgan A.J., Kieff E., Ellis R.W. Varicella-zoster virus as a live vector for the expression of foreign genes. Proc. Natl. Acad. Sci. USA. 84:1987;3896-3900.
7. Madej M., Conway M.J., Morgan A.J., Sweet J., Wallace L., Arrand J., Mackett M. Purification and characterisation of Epstein-Barr virus gp340/220 produced by a bovine papilloma virus vector system. Vaccine. 10:1992;777-782.
8. Morgan, A.J., 1996. Vaccination against Epstein-Barr virus infection. In Barbanti-Brodano, G., Bendinelli, M., Friedman, H. (Eds.), DNA Tumour Viruses: Oncogenic Mechanisms. Plenum, New York, pp. 395-419.
9. Morgan, A.J., Wilson, A.D., 1997. EBV Vaccines. Epstein-Barr Virus Report 4, 33-39. Leeds University Press, Leeds, UK.
10. Morgan A.J., Mackett M., Finerty S., Arrand J.R., Scullion F., Epstein M.A. Recombinant vaccinia virus expressing Epstein-Barr virus glycoprotein gp340 protects cottontop tamarins against EB virus-induced malignant lymphomas. J. Med. Virol. 25:1988;189-195.
11. Morgan A.J., Finerty S., Lovgren K., Scullion F.T., Morein B. Prevention of Epstein-Barr (EB) virus-induced lymphoma in cottontop tamarins by vaccination with the EB virus envelope glycoprotein gp340 incorporated into immune-stimulating complexes. J. Gen. Virol. 69:1988;2093-2096.
12. Morgan A.J., Allison A.C., Finerty S., Scullion F.T., Byars N.E., Epstein M.A. Validation of a first-generation Epstein-Barr virus vaccine preparation suitable for human use. J. Med. Virol. 29:1989;74-78.
13. Nemerow G.R., Mold C., Schwend V.K., Tollefson V., Cooper N.R. Identification of gp350 as the viral glycoprotein mediating attachment of Epstein-Barr virus (EBV) to the EBV/C3d receptor of B cells: sequence homology of gp350 and C3 complement fragment C3d. J. Virol. 61:1987;1416-1420.
14. Nemerow G.R., Houghten R.A., Moore M.D., Cooper N.R. Identification of an epitope in the major envelope protein of Epstein-Barr virus that mediates viral binding to the B lymphocyte EBV receptor (CR2). Cell. 56:1989;369-377.
15. North J.R., Morgan A.J., Epstein M.A. Observations on the EB virus envelope and virus-determined membrane antigen (MA) polypeptides. Int. J. Cancer. 26:1980;231-240.
16. Pearson G., Dewey F., Klein G., Henlé G., Henlé W. Relation between neutralization of Epstein-Barr virus and antibodies to cell-membrane antigens induced by the virus. J. Natl. Cancer Inst. 45:1970;989-995.
17. Pither R., Zhang C.X., Shiels C., Tarlton J., Finerty S., Morgan A.J. Mapping of B-cell epitopes on the polypeptide chain of the Epstein-Barr virus major envelope glycoprotein and candidate vaccine molecule gp340. J. Virol. 66:1992;1246-1251.
18. Pither R.J., Nolan L., Tarlton J., Walford J., Morgan A.J. Distribution of epitopes within the amino acid sequence of the Epstein-Barr virus major envelope glycoprotein, gp340, recognized by hyperimmune rabbit sera. J. Gen. Virol. 73:1992;1409-1415.
19. Qualtière L.F., Decoteau J.F., Hassan Nasr-el-Din M. Epitope mapping of the major Epstein-Barr virus outer envelope glycoprotein gp350/220. J. Gen. Virol. 68:1987;535-543.
20. Ragot T., Finerty S., Watkins P.E., Perricaudet M., Morgan A.J. Replication-defective recombinant adenovirus expressing the Epstein-Barr virus (EBV) envelope glycoprotein gp340/220 induces protective immunity against EBV-induced lymphomas in the tamarin. J. Gen. Virol. 74:1993;501-507.
21. Reed L.J., Muench H. A simple method for estimating fifty per cent end-points. Am. J. Hygiene. 27:1938;493-497.
22. Rickinson, A.B., Kieff, E., 1996. Epstein-Barr virus. In Fields, B.N., Knipe, D.M., Howley, P.M., Chanock, R.M., Melnick, J.L., Monath, T.P., Roizman, B. (Eds.), Field's Virology. Lippincott-Raven, New York, pp. 2397-2446.
23. Sixbey J.W., Yao Q.Y. Immunoglobulin A-induced shift of Epstein-Barr virus tissue tropism. Science. 255:1992;1578-1580.
24. Tanner, J., Whang, Y., Sample, J., Sears, A., Kieff, E., 1988. Soluble gp350/220 and deletion mutant glycoproteins block Epstein-Barr virus adsorption to lymphocytes. J. Virol. 62, 4452-4464.
25. Zhang P.F., Klutch M., Armstrong G., Qualtière L., Pearson G., Marcus S.C.J. Mapping of the epitopes of Epstein-Barr virus gp350 using monoclonal antibodies and recombinant proteins expressed in Escherichia coli defines three antigenic determinants. J. Gen. Virol. 72:1991;2747-2755.